Kamada extends Glassia agreement with Baxalta

17 October 2015

Israel-based plasma-derived protein therapeutics company Kamada (TASE: KMDA) has announced the third extension to supply Glassia to US drugmaker Baxa lta (NYSE: BXLT), which recently separated from Baxter International, under its strategic agreement with Baxter originally executed in August 2010.

Through the extended agreement, Kamada secured around $50 million in additional minimum revenues of Glassia, the company’s proprietary, ready-to-infuse liquid alpha-1 antitrypsin (AAT) treatment that is indicated as a chronic augmentation and maintenance therapy in adults with clinically evident emphysema due to severe congenital AAT deficiency (AATD), through 2018. Under the original agreement (The Pharma Letter August 26, 2010), Baxter committed to a minimum purchase quantity of $60 million over five years.

Anticipated revenue stream

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK